Clinical Proteomics in Kidney Disease: From Discovery to Clinical Application

Open access

Abstract

Proteome analysis has been applied in multiple studies in the context of chronic kidney disease, aiming at improving our knowledge on the molecular pathophysiology of the disease. The approach is generally based on the hypothesis that proteins are key in maintaining kidney function, and disease is a clinical consequence of a significant change of the protein level. Knowledge on critical proteins and their alteration in disease should in turn enable identification of ideal biomarkers that could guide patient management. In addition, all drugs currently employed target proteins. Hence, proteome analysis also promises to enable identifying the best suited therapeutic target, and, in combination with biomarkers, could be used as the rationale basis for personalized intervention. To assess the current status of proteome analysis in the context of CKD, we present the results of a systematic review, of up-to-date scientific research, and give an outlook on the developments that can be expected in near future. Based on the current literature, proteome analysis has already seen implementation in the management of CKD patients, and it is expected that this approach, also supported by the positive results generated to date, will see advanced high-throughput application.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Jha V Garcia-Garcia G Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888): 260-272.

  • 2. Pontillo C and Mischak H. Urinary peptide-based classifier CKD273: towards clinical application in chronic kidney disease. Clinical Kidney Journal. 2017; 10(2): 192-201.

  • 3. Albalat A Mischak H and Mullen W. Urine proteomics in clinical applications: technologies principal considerations and clinical implementation. Prilozi. 2011; 32(1): 13-44.

  • 4. Thongboonkerd V. Proteomic analysis of renal diseases: unraveling the pathophysiology and biomarker discovery. Expert Rev Proteomics. 2005; 2(3): 349-366.

  • 5. Andersen S Mischak H Zürbig P et al. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol. 2010; 11(1): 29-

  • 6. Stalmach A Albalat A Mullen W and Mischak H. Recent advances in capillary electrophoresis coupled to mass spectrometry for clinical proteomic applications. Electrophoresis. 2013; 34(11): 1452-1464.

  • 7. Pontillo C Filip S Borras DM et al. CE-MS-based proteomics in biomarker discovery and clinical application. Proteomics Clin Appl. 2015; 9(3-4): 322-334.

  • 8. Kaiser T Hermann A Kielstein J.T. et al. Capillary electrophoresis coupled to mass spectrometry to establish polypeptide patterns in dialysis fluids. J Chromatogr A. 2003; 1013(1-2): 157-171.

  • 9. Wittke S Fliser D Haubitz M et al. Determination of peptides and proteins in human urine with capillary electrophoresis–mass spectrometry a suitable tool for the establishment of new diagnostic markers. J Chromatogr A. 2003; 1013(1-2): 173-181.

  • 10. Mischak H Vlahou A and Ioannidis JP. Technical aspects and inter-laboratory variability in native peptide profiling: The CE-MS experience. Clin Biochem. 2013; 46(6): 432-443.

  • 11. Metzger J Kirsch T Schiffer E et al. Urinary excretion of twenty peptides forms an early and accurate diagnostic pattern of acute kidney injury. Kidney Int. 2010; 78(12): 1252-1262.

  • 12. Delles C Schiffer E von Zur MC et al. Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals. J Hypertens. 2010; 28(11): 2316-2322.

  • 13. Lankisch TO Metzger J Negm AA et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011; 53(3): 875-884.

  • 14. Alkhalaf A Zürbig P Bakker SJ et al. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One. 2010; 5(10): e13421-

  • 15. Rossing K Mischak H Dakna M et al. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol. 2008; 19(7): 1283-1290.

  • 16. Good DM Zürbig P Argiles A et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010; 9(11): 2424-2437.

  • 17. Dakna M Harris K Kalousis A et al. Addressing the challenge of defining valid proteomic biomarkers and classifiers. BMC Bioinformatics. 2010; 11: 594-

  • 18. Mischak H Delles C Klein J and Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers and clinical application. Adv Chronic Kidney Dis. 2010; 17(6): 493-506.

  • 19. Zürbig P Jerums G Hovind P et al. Urinary Proteomics for Early Diagnosis in Diabetic Nephropathy. Diabetes. 2012; 61(12): 3304-3313.

  • 20. Roscioni SS de ZD Hellemons ME et al. A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia. 2012; 56(2): 259-267.

  • 21. Argiles A Siwy J Duranton F et al. CKD273 a New Proteomics Classifier Assessing CKD and Its Prognosis. PLoS One. 2013; 8(5): e62837-

  • 22. Ovrehus MA Zurbig P Vikse BE and Hallan SI. Urinary proteomics in chronic kidney disease: diagnosis and risk of progression beyond albuminuria. Clin Proteomics. 2015; 12(1): 21-

  • 23. Molin L Seraglia R Lapolla A et al. A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. J Proteomics. 2012; 75(18): 5888-5897.

  • 24. Nkuipou-Kenfack E Duranton F Gayrard N et al. Assessment of metabolomic and proteomic biomarkers in detection and prognosis of progression of renal function in chronic kidney disease. PLoS ONE. 2014; 9(5): e96955-

  • 25. Siwy J Schanstra JP Argiles A et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transplant. 2014; 29(8): 1563-1570.

  • 26. Lindhardt M Persson F Currie G et al. Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open. 2016; 6(3): e010310-

  • 27. Nielsen SE Persson F Frandsen E et al. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med. 2012; 29(8): e184-e190.

  • 28. Lindhardt M Persson FI Oxlund C. et al. Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension. Nephrol Dial Transplant. 2016; in press

  • 29. Schanstra JP Zurbig P Alkhalaf A et al. Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides. J Am Soc Nephrol. 2015; 26(8): 1999-2010.

  • 30. Gu YM Thijs L Liu YP et al. The urinary proteome as correlate and predictor of renal function in a population study. Nephrol Dial Transplant. 2014;

  • 31. Kuznetsova T Mischak H Mullen W and Staessen JA. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J. 2012; 33(18): 2342-2350.

  • 32. Lindhardt M Persson F Zurbig P et al. Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients a substudy of the DIRECT-Protect 2 study. Nephrol Dial Transplant. 2016; in press

  • 33. Pontillo C Jacobs L Staessen JA et al. A Urinary proteome-based Classifier for the early Detection of Decline in Glomerular Filtration. Nephrol Dial Transplant. 2016; in press

  • 34. Schievink B Kropelin T Mulder S et al. Early renin-angiotensin system intervention is more beneficial than late intervention in delaying endstage renal disease in patients with type 2 diabetes. Diabetes Obes Metab. 2016; 18(1): 64-71.

  • 35. Critselis E and Lambers HH. Utility of the CKD273 peptide classifier in predicting chronic kidney disease progression. Nephrol Dial Transplant. 2016; 31(2): 249-254.

  • 36. Siwy J Zürbig P Argiles A et al. Non-invasive diagnosis of chronic kidney diseases using urinary proteome analysis. Nephrol Dial Transplant. 2016; in press

  • 37. Papale M Di Paolo S Magistroni R et al. Urine Proteome Analysis May Allow Noninvasive Differential Diagnosis of Diabetic Nephropathy. Diabetes Care. 2010; 33(11): 2409-2415.

  • 38. Piyaphanee N Ma Q Kremen O et al. Discovery and initial validation of alpha 1-B glycoprotein fragmentation as a differential urinary biomarker in pediatric steroid-resistant nephrotic syndrome. Proteomics Clinical Applications. 2011; 5(5-6): 334-342.

  • 39. Wu TF Fu YY Brekken D et al. Urine Proteome Scans Uncover Total Urinary Protease Prostaglandin D Synthase Serum Amyloid P and Superoxide Dismutase as Potential Markers of Lupus Nephritis. Journal of Immunology. 2010; 184(4): 2183-2193.

  • 40. Kalantari S Rutishauser D Samavat S et al. Urinary Prognostic Biomarkers and Classification of IgA Nephropathy by High Resolution Mass Spec Coupled with Liquid Chromatography. PLoS One. 2013; 8(12)

  • 41. Graterol F Navarro-Munoz M Ibernon M et al. Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling. BMC Nephrology. 2013; 14

  • 42. Pesic I Stefanovic V Muller GA et al. Identification and validation of six proteins as marker for endemic nephropathy. Journal of Proteomics. 2011; 74(10): 1994-2007.

  • 43. Lim SC Liying DQ Toy WC et al. Adipocytokine zinc alpha(2) glycoprotein (ZAG) as a novel urinary biomarker for normo-albuminuric diabetic nephropathy. Diabetic Medicine. 2012; 29(7): 945-949.

  • 44. ito-Martin A Ucero AC Zubiri I et al. Osteoprotegerin in Exosome-Like Vesicles from Human Cultured Tubular Cells and Urine. PLoS One. 2013; 8(8)

  • 45. Gonzalez-Calero L Martin-Lorenzo M de la Cuesta F et al. Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. Cardiovascular Diabetology. 2016; 15

  • 46. Gold L Ayers D Bertino J et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One. 2010; 5(12): e15004-

  • 47. Holzer M Birner-Gruenberger R Stojakovic T et al. Uremia Alters HDL Composition and Function. Journal of the American Society of Nephrology. 2011; 22(9): 1631-1641.

  • 48. Weichhart T Kopecky C Kubicek M et al. Serum Amyloid A in Uremic HDL Promotes Inflammation. Journal of the American Society of Nephrology. 2012; 23(5): 934-947.

  • 49. Takahashi K Wall SB Suzuki H et al. Clustered O-Glycans of IgA1. Molecular & Cellular Proteomics. 2010; 9(11): 2545-2557.

  • 50. Piroddi M Palmese A Pilolli F et al. Plasma nitroproteome of kidney disease patients. Amino Acids. 2011; 40(2): 653-667.

  • 51. Antonelou MH Kriebardis AG Velentzas AD et al. Oxidative stress-associated shape transformation and membrane proteome remodeling in erythrocytes of end stage renal disease patients on hemodialysis. Journal of Proteomics. 2011; 74(11): 2441-2452.

  • 52. varez-Llamas G Zubiri I Maroto AS et al. A role for the membrane proteome in human chronic kidney disease erythrocytes. Translational Research. 2012; 160(5): 374-383.

  • 53. Luczak M Formanowicz D Pawliczak E et al. Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome Science. 2011; 9

  • 54. Luczak M Formanowicz D Marczak L et al. Deeper insight into chronic kidney disease-related atherosclerosis: comparative proteomic studies of blood plasma using 2DE and mass spectrometry. Journal of Translational Medicine. 2015; 13

  • 55. Luczak M Suszynska-Zajczyk J Marczak L et al. Label-Free Quantitative Proteomics Reveals Differences in Molecular Mechanism of Atherosclerosis Related and Non-Related to Chronic Kidney Disease. International Journal of Molecular Sciences. 2016; 17(5)

  • 56. Glorieux G Mullen W Duranton F et al. New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol Dial Transplant. 2015; 30(11): 1842-1852.

  • 57. Antonelou MH Georgatzakou HT Tzounakas VL et al. Blood modifications associated with end stage renal disease duration progression and cardiovascular mortality: a 3-year follow-up pilot study. Journal of Proteomics. 2014; 101: 88-101.

  • 58. Butte AJ Sigdel TK Wadia PP et al. Protein Microarrays Discover Angiotensinogen and PRKRIP1 as Novel Targets for Autoantibodies in Chronic Renal Disease. Molecular & Cellular Proteomics. 2011; 10(3)

  • 59. Fechete R Heinzel A Perco P et al. Mapping of molecular pathways biomarkers and drug targets for diabetic nephropathy. Proteomics Clinical Applications. 2011; 5(5-6): 354-366.

  • 60. Krochmal M Fernandes M Filip S et al. PeptiCKDdb- peptide- and protein-centric database for the investigation of genesis and progression of chronic kidney disease. Database-the Journal of Biological Databases and Curation. 2016;

  • 61. Dominiczak AF Herget-Rosenthal S Delles C et al. Systems biology to battle vascular disease. Nephrol Dial Transplant. 2010; 25(4): 1019-1022.

  • 62. Molina F Dehmer M Perco P et al. Systems biology: opening new avenues in clinical research. Nephrol Dial Transplant. 2010; 25(4): 1015-1018.

  • 63. Cisek K Krochmal M Klein J and Mischak H. The application of multi-omics and systems biology to identify therapeutic targets in chronic kidney disease. Nephrol Dial Transplant. 2015.

  • 64. EMA. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500169469.pdf. 2014;

  • 65. Pontillo C Zhang Z Schanstra J et al. Prediction of chronic kidney disease stage 3 by CKD273 a urinary proteomic biomarker. Kidney International Reports. 2017; in press

  • 66. Mischak H Delles C Vlahou A and Vanholder R. Proteomic biomarkers in kidney disease: issues in development and implementation. Nat Rev Nephrol. 2015; 11(4): 221-232.

  • 67. Stepczynska A Schanstra JP and Mischak H. Implementation of CE-MS-identified proteome-based biomarker panels in drug development and patient management. Bioanalysis. 2016; 8(5): 439-455.

  • 68. Andresdottir G Jensen ML Carstensen B et al. Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors. Diabetes Care. 2014; 37(6): 1660-1667.

  • 69. Critselis E Vlahou A Stel VS and Morton RL. Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrol Dial Transplant. 2017; in press

  • 70. Klein J Ramirez-Torres A Ericsson A et al. Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice. Kidney Int. 2016; in press

  • 71. Siwy J Zoja C Klein J. et al. Evaluation of the Zucker Diabetic Fatty (ZDF) rat as a model for human disease based on urinary peptidomic profiles. PLoS One. 2012; 7(12): e51334-

  • 72. Siwy J Schanstra JP Argiles A et al. Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrology Dialysis Transplantation. 2014; 29(8): 1563-1570.

  • 73. Mischak H. Pro: Urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrol Dial Transplant. 2015; 30(4): 532-537.

Search
Journal information
Impact Factor


CiteScore 2017: 0.45

SCImago Journal Rank (SJR) 2018: 0.177

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 467 295 40
PDF Downloads 316 209 39